Post-traumatic stress disorder (PTSD) is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives in the U.S. PTSD generally occurs more often in women than men. It is natural for a person to be feared during or after a traumatic situation, this fear triggers alteration of many split-seconds in the body to defend against danger. Fight-or-flight response is one of the essential body’s defensive mechanism that protects body in adverse situations. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD is categorized as chronic PTSD and acute PTSD. It has been observed that the military soldiers also suffer from PTSD. According to the PSTD foundation of America, around 245 soldiers in the U.S. committed suicide, in the year 2009, due to the disease. Since 2006, 1,100 troops suicides have been recorded in the U.S. and the number is still increasing. According to Anxiety and Depression Association of America, around 7.7 million Americans, aged 18 years or above are found to suffer from PTSD.
Considerable growth is expected in the PTSD therapeutic pipeline, attributed to increasing prevalence of the disease, further aggravated by stressful lifestyle. Funds from the various non-profit organization such as, PTSD Foundation of America, Anxiety and Depression Association of America, Defense Centers of Excellence for Psychological Health & Traumatic Brain Injury. are supporting the development of therapeutic pipeline of the disease. Increasing collaboration between educational institutes and pharmaceutical companies is also one of the factors for growth of PTSD pipeline. In addition, many patents have also been approved during the development of the drug candidates for the treatment of the disease. As of June 2017, the PTSD pipeline comprises of approximately 23 drug candidates in different stages of development.
NUMBER OF PTSD DRUG CANDIDATES UNDER DEVELOPMENT (2017)
Some of the key players developing drugs for the treatment of PTSD include India Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies, Inc. and others.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles